The data, published in the journal JAMA, showed patients who were obese and without diabetes experienced a 14% weight regain nearly a year after they switched to a placebo from an eight-month course of Lilly's Zepbound. Meanwhile, those who continued the treatment experienced an additional 5.5% weight reduction during the 52-week period, data from the study showed. Shares of Eli Lilly fell over 4% in morning trading.